In the last month, Lumber Liquidators’ (NYSE: LL) stock has outperformed Restoration Hardware (NYSE: RH) by a ratio of 5:1, as the two companies battle as the best up-and-coming home improvement retail company in the U.S. In terms of market capitalization, one-year stock performance, and growth, the two companies are near identical. However, moving forward over the next few months, I think one stock is best positioned for more »
In late July, Facebook (NASDAQ: FB) announced plans to utilize video advertising. Then, on August 15, Facebook confirmed to AllThingsD that a payment processing system is in the works. While these two catalysts complement the company’s surprising quarterly beat, and its impressive monetization of mobile, the big question is how fundamentally impactful could these services be?
First, let’s acknowledge the fact that Facebook’s valuation has more »
It’s hard to believe that Hewlett-Packard (NYSE: HPQ) has been the Dow Jones’ best performer in 2013. The stock has rallied 90% while revenue and quarterly earnings have fallen 10% and 32%, respectively, year-over-year. The reason for its gain relates to the value call, but is Hewlett-Packard really the best option in its space?
The Value Call
After a two-year 65% loss from 2011-2013, investors began shouting that HP more »
BlackBerry (NASDAQ: BBRY) has soared higher by 11% in the last three days behind news of a special committee being formed at the company. This committee has one job: to seek strategic alternatives, including joint ventures or a sale of the company. But how will this story end?
A Run-Down Of Events
Essentially, 11% has been added to BlackBerry’s stock in anticipation of either a takeover or a partnership more »
With Carl Icahn’s twitter disclosure, Apple (NASDAQ: AAPL) has exploded, and fears of future loss may be a concern of the past. Now, investors turn their attention to past recoveries such as Green Mountain Coffee Roasters and Netflix as a guide of what could happen next. However, what’s more alarming is what could happen with its competitors.
A Great Rotation Of Capital
Apple’s closest competitors are Samsung more »
For the last seven years, Amazon (NASDAQ: AMZN) has been a solid performer. Now the stock has exceeded the price targets of many analysts, is it time to sell the stock
Why so negative?
Nearly every bear case I hear with regards to Amazon surrounds either its forward earnings multiple or its margins. However, Amazon is notorious for spending nearly all of its gross profit -- $4.5 billion last quarter more »
Last week, the market witnessed its biggest three-day loss in months. Post-earnings movers have attracted investors' eyes as a place to find value. However, are any of these post-earnings movers presenting upside after earnings?
A point of excessive expectations
Zillow (NASDAQ: Z) has seen an incredible 200% rally in 2013, but last week, it fell 9% after missing on the bottom line and barely beating expectations on the top line more »
Michael Kors (NYSE: KORS) traded higher by almost 4% after the company announced its fiscal Q1 earnings report. Furthermore, Michael Kors has significantly outperformed other big name retailers who have already reported earnings. However, stock performance is not the only measure where Kors is thriving.
An important metric in retail
In retail, one of the most important metrics is comparable or same-store sales. This metric shows how a company’s more »
The Internet Services space has been one of the top performing sectors of 2013, increasing more than 75%. In many ways, the performance is reminiscent of the dot-com era; the only difference is that internet companies today have actual growth -- not just speculation. With that said, certain internet stocks have played a larger role in driving this industry higher, but do these stocks have more upside in store?
Online real more »
ACADIA Pharmaceuticals (NASDAQ: ACAD) and Celldex Therapeutics (NASDAQ: CLDX) have become two of the best performing biotech stocks of the last 16 months. ACADIA has significantly outperformed Celldex during this period, but today, both stocks trade at prices pretty close to each other. Therefore, with prices just shy of $20, which stock will rise to $30 first, and become the best performer?
A glance at both companies
Both companies have more »
We saw some massive post-earning moves last week, but are these moves justified, and is there more upside ahead? Sure, earnings can reverse the trend of a stock or push a momentum stock even higher, but sometimes these moves can be a trap. Therefore, let’s take a look at four of these controversial movers.
Back From the Dead
Stocks move higher and lower everyday, but during earnings season these moves are particularly important because they are fundamentally induced. With earnings season near complete, we still have a few companies that could impress Wall Street. Therefore, let’s determine if Friday’s top earnings-related movers are a buy.
Fast-Growing But Expensive Company
Last week, there were several massive stock-moving IPOs, but one in particular caught my attention, and that’s Cvent (NYSE: CVT). In my opinion, investors might be paying way too much for the stock, and here’s why.
The Business of Events
Cvent is a cloud-based company, operating in two different segments: event and meeting planners and then hotels and venues. The company’s cloud platform is used to help more »
Aside from solar, no industry in the market has been more beaten down over the last few years than coal. With that said, solar stocks saw a rebound earlier this year, and now with decent data and shifting outlooks, many believe it is now time to buy coal stocks – but is it?
Since January 2011, coal stocks have been the worst performers in the stock market. Take a more »
Ariad Pharmaceuticals’ (NASDAQ: ARIA) Iclusig and Amarin Corporation’s (NASDAQ: AMRN) Vascepa may have been two of the most hyped drugs of the last few years, but Uceris from Santarus (NASDAQ: SNTS) has stolen the spotlight. This is a drug that is beating all sales expectations, and leading some to wonder if Santarus’ impressive stock rally can continue.
Three Drugs With Different Outlooks
The reason that these three companies, and more »
After a 360% gain in 2013, you might have missed the boat on Tesla (NASDAQ: TSLA). As of now, much of its valuation is based on future earnings, and with the stock trading higher by another 15% last week, I think there is a considerable amount of risk present. Therefore, let’s look at three specific problems that could put a damper on Tesla’s trend higher.
1. It’s more »
On Tuesday, several of biotechnology’s hottest names announced earnings. Despite strong results, the market appears to have grown accustomed to perfection. Therefore, can these stocks go any higher? Or, have these stocks reached their peak?
New Product Launch Suggests More Upside
CVS Caremark’s (NYSE: CVS) earnings pushed the entire pharmacy space lower on Tuesday, but was the report really that bad, and are stocks in the industry worth buying?
The patent cliff
CVS ticked lower by almost 3% on Tuesday, taking the stock’s year-to-date gains to 24%. For the quarter, we saw the recurring event of weaker revenue and higher margins caused by new generic introductions.
CVS’ revenue grew more »
On a somewhat flat trading session, shares of Ford Motor Company (NYSE: F) abruptly dropped lower by 1.77%. Strangely, in a space that typically trades very close, General Motors (NYSE: GM) fell lower by just 0.5%. The drop is related to news concerning a 50-year old tariff, but is this news fundamentally important, and does the loss create a buying opportunity?
What’s The News?
News broke early more »
It’s never wise to buy on the recommendation of one analyst alone, but you can use the reasons for the call to help make a more informed investment decision. With that said, there were some controversial calls on Monday, but are these analysts right, or does the call create a trap for retail investors?
The upgrades continue to pour in
- Page 1 of 28